1. Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure–Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides
- Author
-
Shreyas Deshpande, Rashmi Talwar, Ganesh Navinchandra Gote, Jayasagar Gundu, Rupali Vyawahare, Shashikant Pawar, Akshaya Wagh, Talha Khan, Anil Kalia, Venkata P. Palle, Usha Dhayagude, M. K. Singh, Pradeep Patil, Ganesh Chaure, Praveen Kumar Gupta, Amit Das, Vijay Kanoje, Sharad Sharma, Vidya Ramdas, Vinod Patil, Rajesh Yeshodharan, Prashant B. Nigade, Dipak Modi, Dnyaneshwar Warude, Dilip Pandey, Jagadeesh Daler, Mahammad Azhar, Arun Nayak, Sneha Joshi, Sudipto Das, Rajender Kumar Kamboj, Javed S Shaikh, Maneesh Mehta, Deepak Sahebrao Walke, Rajesh V. Gupta, Himani Pareek, Kumar V S Nemmani, Parag Joshi, Mahip Verma, Vinod Mali, Laxmikant Datrange, Santosh Parkale, Rajesh Loriya, Vaibhav Kalhapure, Geetika Sharma, Ravindra R. Pal, Sagar Budhe, Gautam Agarwal, Sachin Suravase, Sagar Darekar, Mark G. Bock, Advait Arun Joshi, Moloy Banerjee, Smita Bhoskar, Amitesh Kishore, and Dhananjay Bakhle
- Subjects
0303 health sciences ,Bicyclic molecule ,Sulfonamide (medicine) ,Indane ,Pharmacology ,01 natural sciences ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,03 medical and health sciences ,chemistry.chemical_compound ,chemistry ,Pharmacokinetics ,Drug Discovery ,Neuropathic pain ,medicine ,Molecular Medicine ,Structure–activity relationship ,Thiazole ,CYP2C9 ,030304 developmental biology ,medicine.drug - Abstract
Voltage-gated sodium channel NaV1.7 is a genetically validated target for pain. Identification of NaV1.7 inhibitors with all of the desired properties to develop as an oral therapeutic for pain has been a major challenge. Herein, we report systematic structure-activity relationship (SAR) studies carried out to identify novel sulfonamide derivatives as potent, selective, and state-dependent NaV1.7 inhibitors for pain. Scaffold hopping from benzoxazine to chroman and indane bicyclic system followed by thiazole replacement on sulfonamide led to identification of lead molecules with significant improvement in solubility, selectivity over NaV1.5, and CYP2C9 inhibition. The lead molecules 13, 29, 32, 43, and 51 showed a favorable pharmacokinetics (PK) profile across different species and robust efficacy in veratridine and formalin-induced inflammatory pain models in mice. Compound 51 also showed significant effects on the CCI-induced neuropathic pain model. The profile of 51 indicated that it has the potential for further evaluation as a therapeutic for pain.
- Published
- 2020
- Full Text
- View/download PDF